NATIONAL COMPREHENSIVE CANCER NETWORK

About TRAZIMERA Loading TRAZIMERA is FDA approved across all indications of Herceptin® 1 Indications Loading FDA-approved biosimilars such as trastuzumab-qyyp (TRAZIMERA®) are recommended as appropriate substitutes for trastuzumab in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) 1,4,5*†‡ Pfizer Oncology Together™: Making your patients' support needs a priority. Together. Co-Pay Assistance Loading Dosing, resources, and biosimilars portfolio Available in single- and multiple-dose options... This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only... Access Resources Loading Backed by the Pfizer commitment With 15+ years of biosimilars experience globally, including more than 1.3 million people treated around the world 2,6 Learn More Loading References NCCN=National Comprehensive Cancer Network.*Biosimilar..

Also known as: National Comprehensive Cancer Network, Inc